Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

Metastatic Breast ◽

Japanese Women ◽

Weekly Paclitaxel ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Abstract P6-17-14: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical trial for the SBCCSG-36 investigators

10.1158/1538-7445.sabcs18-p6-17-14 ◽

2019 ◽

Author(s):

K Inoue ◽

J Ninomiya ◽

K Okubo ◽

T Nakakuma ◽

H Yamada ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Investigational New Drugs ◽

10.1007/s10637-019-00773-9 ◽

2019 ◽

Vol 37 (3) ◽

pp. 592-593

Author(s):

Kenichi Inoue ◽

◽

Jun Ninomiya ◽

Tsuyoshi Saito ◽

Katsuhiko Okubo ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Investigational New Drugs ◽

10.1007/s10637-019-00755-x ◽

2019 ◽

Vol 37 (3) ◽

pp. 538-547 ◽

Cited By ~ 3

Author(s):

Kenichi Inoue ◽

◽

Jun Ninomiya ◽

Tsuyoshi Saito ◽

Katsuhiko Okubo ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1055/s-0041-1730221 ◽

2021 ◽

Author(s):

A Schneeweiss ◽

D Miles ◽

E Ciruelos ◽

F Puglisi ◽

T Peretz-Yablonski ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Global Study ◽

Locally Recurrent

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4592-y ◽

2017 ◽

Vol 168 (2) ◽

pp. 337-348 ◽

Cited By ~ 2

Author(s):

Y. F. Yu ◽

Y. Wang ◽

T. P. Fu ◽

K. Chen ◽

J. Q. Liu ◽

...

Keyword(s):

Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Single Agent Chemotherapy

Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.636 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 636-636

Author(s):

V. Guillem Porta ◽

M. Martin ◽

M. Gil Gil ◽

P. Kellokumpu-Lehtinen ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Cardiac Function ◽

Clinical Response ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.587 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 587-587 ◽

Cited By ~ 2

Author(s):

A. Chan ◽

L. Petruzelka ◽

M. Untch ◽

M. Martin ◽

M. Gil Gil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Her2 Positive ◽

Term Survival ◽

First Line Therapy ◽

A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90846-4 ◽

2004 ◽

Vol 2 (3) ◽

pp. 127 ◽

Cited By ~ 1

Author(s):

M Untch ◽

S Kahlert ◽

L Petruzelka ◽

M Martin ◽

V Guillem-Porta ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Retrospective review of Her2 positive metastatic breast cancer patients who received Pertuzumab and Herceptin as a first line therapy at KFSH&RC (single institute experience) from 2013 to 2016

The Breast ◽

10.1016/s0960-9776(19)30245-0 ◽

2019 ◽

Vol 44 ◽

pp. S64

Author(s):

K. Suleman ◽

A. Mushtaq ◽

E. Haque ◽

A. Badran ◽

D. Ajarim ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Retrospective Review ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent